0000000000677161
AUTHOR
Benoit Romain
showing 3 related works from this author
Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter R…
2020
BACKGROUND Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added…
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…
2021
International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…
Analyse coût-efficacité associée à l’utilisation des prothèses pariétales biosynthétiques résorbables comparativement aux prothèses biologiques dans …
2020
Etat de la question La prothese biosynthetique Phasix® n’a jamais fait l’objet d’etude comparative avec les protheses biologiques lors de cure d’eventration en milieu contamine. Des donnees complementaires etaient necessaires pour confirmer la transition vers les protheses biosynthetiques resorbables et justifier l’homogeneisation des pratiques chirurgicales. Le but de cette etude etait de comparer, en termes de cout et de complications graves, l’utilisation des protheses parietales biosynthetiques resorbables et biologiques chez les patients beneficiant d’une cure d’eventration contaminee (grade 3 du « Modified Ventral Hernia Working Group »). Materiel et methodes Une analyse cout-efficaci…